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Purpose: The purpose of this study was to determine the effects of patient characteristics, 
blood rheology, and plasma biochemistry on the outcome ofinfrainguinal bypass grafting. 
Methods: Blood theology, plasma fibrinogen, cross-linked fibrin degradation products, yon 
WiUebrand factor (vWf) and other endothelial products, and clinical variables including 
smoking markers were determined before surgery in patients with 184 consecutive 
infrainguinal bypass grafts (90 vein, 94 synthetic grafts). 
Results: Fifty (27%) graft occlusions and 17 (9%) deaths occurred within I year of surgery. 
On tmivariate analysis a poor outcome was associated with elevated preoperative plasma 
fibrinogen, fibrin degradation products, vWf, and platelet levels, reduced hemoglobin and 
systolic ankle pressure, a below-knee anastomosis, a decrease in patent calf vessels, and the 
presence of tissue necrosis (all p < 0.001). On multivariate analysis increased preoperative 
vWf levels were predictive of poor postoperative outcome (relative hazard for upper 
quartile versus lower quartile = 1.82), as were a low systolic ankle pressure (relative 
hazard = 2.51), presence of tissue necrosis (relative hazard = 2.73), and female sex 
(relative hazard = 1.9). None of the other variables tudied was related to outcome. With 
a preoperative risk score derived from the results, graft patency rates within 3 months of 
surgery fell to less than 25% with risk scores in the upper quartile. 
Conclusions: Preoperative measurement of plasma vWf may enable more accurate predic- 
tion of the outcome of infrainguinal revascularization a d when combined with other 
variables could assist in patient selection for these procedures. The association ofvWfwith 
graft occlusion supports arole for endothelial disturbance in graft occlusion. (J Vase Surg 
1996;24:639-46.) 
The superficial femoral artery is the commonest 
site of symptomatic peripheral arterial occlusive dis- 
ease, ~ yet the outcome after femoropopliteal nd 
femoro-distal grafting 2,3 remains less successful than 
the outcome of proximal reconstruction. 4 The me- 
chanical factors that influence the outcome ofinfrain- 
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guinal bypass grafting include the quality of runoff 
vessels and graft material used, s-7 and it has recently 
been acknowledged that intrinsic patient hypercoagu- 
lability may also contribute to graft failure, s Elevated 
blood viscosity has been shown to reduce blood flow 
within lower limb vessels, 8 and elevated plasma fi- 
brinogen is associated with graft occlusion. 9'1° Sub- 
endothelial proliferation and thrombosis play key 
roles in graft occlusion, 11-13 and animal studies have 
indicated that the endothelial product von Willebrand 
factor (vWf) is an essential requirement for the devel- 
opment of occlusive thrombi at sites of arterial in- 
jury.14 The adverse ffects of smoking on graft patency 
may be partly mediated through plasma fibrinogen, 1° 
and perhaps through endothelial disturbance and 
other prothrombotic effects? 5 
We therefore xamined in a prospective study the 
influence of fibrinogen, fibrin degradation products 
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(FDP, a marker of fibrin turnover), vWf, and other 
endothelial markers and thrombotic tests, in addition 
to smoking habit and other clinical risk factors, on the 
outcome of infrainguinal revascularization surgery. 
PATIENTS AND METHODS 
Patients. A total of 186 consecutive infrainguinal 
bypass grafts in 165 patients attending the Unit for 
Peripheral Vascular Surgery, Glasgow Royal Infir- 
mary, and the Vascular Surgery Unit, Gartnavel Gen- 
eral Hospital, were recruited into this study before 
undergoing surgery and were monitored for up to 1 
year after surgery. A total of 14 grafting procedures 
were performed as emergency procedures in patients 
with acute sensorimotor impairment associated with 
arterial occlusion. The remaining 172 grafts were all 
carried out on routine operating lists. A detailed 
history and examination were obtained from each 
patient, and informed consent for participation i the 
study was obtained, the study protocol having been 
approved by the local ethics committee. The extent of 
arterial disease in each patient was assessed with the 
angiographic s oring system described by Bollingcr ct 
al.16 This system produces a numeric total based on 
assessment of defined arterial segments, with higher 
totals reflecting more extensive disease. 
Venous blood samples were obtained without 
stasis before surgery, and patients were reviewed at the 
vascular laboratory at 3, 6, and 12 months after 
surgery or until graft occlusion, whichever was the 
shorter period. Graft patency was assessed by clinical 
examination, measurement of ankle/brachial pres- 
sure indexes, and color duplex scanning with either 
an Acuson 128 Scanner (Acuson Corporation, 
Stcvenage, Hertsfordshire, U.K.), or an ATL Ultra- 
mark 9 (HDI) scanner (Advanced Technology Labo- 
ratories, San Francisco, Calif.). Patient mortality was 
confirmed from hospital records and from the pa- 
tient's own general practitioner where appropriate. 
Most patients who could tolerate antiplatelet 
therapy were taldng aspirin before admission to the 
hospital, but 13 additional patients without contrain- 
dications to aspirin received treatment after surgery. 
No other adjuvant postoperative therapies were used 
to increase graft patency. 
Laboratory methods. Blood sampling was per- 
formed without venous stasis with a 19-gauge but- 
terry needle. A total of 9 ml blood from each sample 
was added to a plastic tube containing 1ml trisodium 
citrate (0.109 mmol/L). The blood was subsequently 
handled, stored, and underwent assay as previously 
described is for plasma fit~rinogen (Clauss assay), 
cross-linked FDP (D-dimer antigen, enzyme-linked 
immunosorbent assay [ELISA], Agen Ltd., Parsip- 
pany, N.J.), vWf (ELISA, Dako, High Wycombe, 
U.K.), plasminogen activator inhibitor (chromogenic 
activity assay, I~biVitrum Ltd. Uxbridge, Middx., 
U.K.), and tissue plasminogen activator antigen 
(ELISA, Biopool TintElize, Biopool AB, Ume/i, Swe- 
den). Fibrinogen and vWf assays were standardized 
with International Standards (NIBSC, Potters Bar, 
U.K.). Rheologic variables (hematocrit, blood and 
plasma viscosity) were measured as previously de- 
scribed ~7 in blood anticoagulated with dipotassium 
edetate (1.5 mg/ml). 
White cell count, platelet count, and hemoglobin 
were determined in a Coulter S counter and red cell 
aggregation by a photometric assay (Myrenne 
GmbH, Roetgen, Germany). Serum albumin and 
globulin levels were determined on an Olympus AU 
5200 analyzer with reagents supplied by Olympus and 
Boehringer Mannheim (UK. Ltd.), whereas erum 
cholesterol levels were measured on separated plasma 
samples with a Hitachi 717 automatic analyzer and 
Boehringer Mannheim (UK. Ltd.) reagents. 
C-reactive protein (CRP) levels were determined 
on an automated nephelometer (Behring Diagnostic, 
Milton Keynes U.K.) with reagcnts supplied by 
Behring Diagnostic. Smoking status was confirmed 
by clinical history and estimation of plasma carboxy- 
hemoglobin in dipotassium ethylenendiamine t t- 
raacetic acid anticoagulated blood on a Co-Oximeter 
282 (Instrumentation Laboratory Ltd., Warrington, 
Cheshire, U.K.) within 6 hours of sampling, whereas 
plasma thiocyanate and cotinine levels were deter- 
mined bcfore surgery and at each subsequent sam- 
pling time with methods previously described) s 
Statistical analyses. Before patient recruitment 
was begun, the statistical design of the study was 
finalized, with power calculations based on the com- 
posite cnd point of graft occlusion or death within 1 
year of surgery being used to define poor outcome. 
These calculations ensured recruitment of adequate 
patient numbers to give the study appropriate statis- 
tical power. 
Univariate analysis of preoperative patient charac- 
teristics, blood rheology, and thrombotic mediators 
were performed by log-rank testing 19 on an IBM- 
compatible microcomputer with the BMDP statistical 
software package, Module 1L (BMDP Statistical 
Software Inc., Cork, Ireland). In patients who under- 
went multiple grafts during the study period, each 
graft was analyzed as a separate procedure, with 
baseline assessments repeated before surgery. In ad- 
dition to the patient background characteristics 
shown in Table I, age, highest systolic ankle pressure 
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 4 Woodburn et al. 641 
Table I. Relation of clinical variables to graft outcome in 184 infrainguinal bypass grafts (Figures in 
parentheses refer to percentage of total for each characteristic) 
Patient characteristic Total (n = 184) Patent (n =117) (%) Occluded (n =50) (%) Died (n = 17) (%) 
Sex 
Male 119 84 (70) 26 (22) 9 (8) 
Female 65 33 (51) 24 (37) 8 (12) 
Coexistent disease 
Other cardiovascular disease 92 57 (62) 25 (27) 10 (11) 
Diabetes 24 12 (50) 6 (25) 6 (25) 
Hypertension 44 29 (66) 12 (27) 3 (7) 
Hyperlipidemia 9 7 (78) 2 (12) 0 
Tissue necrosis/limb sepsis 51 18 (35) 23 (45) 10 (20) 
Previous vascular surgery 92 60 (65) 24 (26) 8 (9) 
Smoking habit 
Nonsmoker 50 29 (58) 15 (30) 6 (12) 
Ex-smoker 42 28 (67) i2 (28) 2 (5) 
Smoker 92 60 (65) 23 (25) 9 (10) 
Medication 
Preoperative antiplatelet agent 61 43 (70) 11 (18) 7 (12) 
Preoperative anticoagulation 7 3 (43) 4 (57) 0 
Postoperative antiplatelet agent 74 54 (73) 13 (17) 7 (10) 
Postoperative anticoagulation 18 9 (50) 9 (50) 0 
Timing of surgery 
Elective surgery 170 112 (66) 45 (26) 13 (8) 
Emergency surgery 14 5 (36) 5 (36) 4 (28) 
Graft material 
Vein graft 90 61 (68) 19 (21) 10 (11) 
Synthetic graft 94 56 (59) 3I (33) 7 (8) 
Distal anastomosis 
Proximal popliteal 115 84 (73) 22 (19) 9 (8) 
Distal popliteal 32 20 (62) 8 (25) 4 (13) 
Cruralvessel 37 13 (35) 20 (54) 4 (i1) 
Calf vessels 
Isolated poplitealsegment 10 6 (60) 3 (30) 1 (10) 
One vessel 50 16 (32) 26 (52) 8 (16) 
Twovessels 54 41 (76) 8 (15) 5 (9) 
Three vessels 70 54 (77) 13 (18) 3 (5) 
Other cardiovascular disease refers to symptomatic ischemic heart disease, atrial fibrillation, transient ischaemic attacks, or completed stroke. 
in the affected limb, and the Bollinger angiogram 
score were included in the analysis of background 
information. For univariate analysis continuous vari- 
ables were arbitrarily subdivided into two groups 
according to whether the value measured was above 
or below the median value for the whole study group. 
This subdivision was not required for the multivariate 
analysis, which was performed with Cox proportional 
hazard models (Module 2L). 
The multivariate analysis was performed in two 
principal parts. Initially the preoperative patient char- 
acteristics were modeled, and thereafter additional 
analyses were performed to assess whether any of the 
preoperative laboratory data could significantly im- 
prove on this model. In view of the highly skewed 
distribution of values of carboxyhemoglobin, FDP, 
plasma cotinine, thiocyanate, and CRP, these vari- 
ables were all analyzed after logarithmic transforma- 
tion was performed. 
RESULTS 
A total of 186 consecutive infrainguinal bypass 
grafts were performed on 165 patients. Seventy (38%) 
of these grafts were undertaken to relieve critical imb 
ischemia. 2° The severity of peripheral arterial disease 
in the study group as determined by the angiogram 
score was distributed in a Gaussian manner. The mean 
age of patients at the time of surgery was 66.2 years 
(SD, 9.4; range, 36 to 89 years). Fifteen patients 
underwent bilateral grafting during the period of the 
study, and a further six patients underwent redo 
bypass grafting after occlusion of  a graft inserted 
during the study period. Seventeen (10%) patients 
died with patent grafts within i year of surgery; all but 
four deaths occurred within 3 months of the opera- 
tion. Eight patients died after a documented cardiac 
event: two of postoperative r spiratory failure, one of 
pulmonary thromboembolism, and six of unknown 
cause. Fifty grafts occluded within 1 year of  surgery, 
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giving a total of 67 grafts that were classified as having 
a poor outcome (occlusion or death). 
Synthetic grafts were removed from two patients 
while still patent, both as a consequence of graft 
infection, and these grafts have been excluded from 
subsequent analyses. Therefore 184 grafts made up 
the study group: 90 vein grafts and 94 synthetic grafts. 
Synthetic grafts consisted of 6-ram-diameter polytet- 
rafluoroethylene or 8-mm gelatin-coated lmittcd Da- 
cron grafts. A number of synthetic grafts had a vein 
patch 21 or cuff 22 interposed at the distal anastomosis 
but were analyzed as synthetic grafts. 
With the exception of two patients unable to 
attend for follow-up, all grafts have been monitored 
for at least a year after surgery, whereas patency of the 
two grafts lost to follow-up has been confirmed by the 
patients' general practitioners. During the 1-year 
period of postoperative graft surveillance, 10 vein 
grafts underwent intervention to prevent occlusion 
(percutaneous angioplasty of stenosis in four grafts, 
operative vein patch angioplasty orinterposition graft 
for stenosis in four, and ligation of arteriovenous 
fistulae in two). The 1-year cumulative primary pa- 
tcncy rates reported in this series therefore refer to 
primary assisted patency rates, which were 70% for 
vein grafts and 60% for synthetic grafts (Fig. 1). 
Patient characteristics. On univariate log rank 
testing anumber of terms were found to be related to 
the time of primary end point, defined as death or 
graft occlusion within 1 year of surgery, the presence 
of preoperative limb sepsis or tissue necrosis, an 
anastomosis to distal popliteal or calf arteries, a 
preoperative systolic anldc pressure below the median 
value of 71 mm Hg (all p < 0.0001), emergency 
revascularization surgery, female sex (both p < 0.01), 
age older than 67 years, and a Bollinger angiogram 
score greater than 106 (both p < 0.05). No evidence 
was seen of an association between a poor outcome 
and graft material or current smoldng habit. The 
postoperative use of antiplatelet therapy (aspirin or 
dipyridamole), however, showed an association with 
incrcascd patency on univariatc analysis (p = 0.02). 
Subsequent multivariate analysis of the patient 
characteristics was carried out on the 131 cases in 
whom all patient background data were complete (88 
good outcomes and 43 poor outcomes [35 occlu- 
sions, 8 deaths]) and indicated that a low systolic ankle 
pressure (p < 0.0001), presence of limb sepsis or 
tissue necrosis (p < 0.01), previous vascular surgery 
(p = 0.02), female sex (p= 0.04), and emergency 
infrainguinal bypass grafting (p = 0.04) were all inde- 
pendently predictive of subsequent death and graft 
occlusion in the year after revascularization surgery. 
Laboratory tests (Table II). On univariate analy- 
sis poor outcome was associated with high levels of 
vWf, fibrinogen, platelet count (all p < 0.0001), FDP 
(p < 0.001) (Fig. 2), CRP (p < 0.01), and white cell 
count (p = 0.03) and with low levels of albumin and 
globulin (both p < 0.001), cholesterol, factor VII, 
and blood viscosity (all p < 0.01). Other laboratory 
variables were unrelated to outcome (Table II). Nei- 
ther the markers of acute smoldng (carboxyhemoglo- 
bin) or chronic smoking (cotinine and thiocyanate) 
were related to the outcome ofinfrainguinal grafting 
on univariate analysis. 
On multivariate analysis, after adjustment was 
made for the effects of significant patient characteris- 
tics (see previous text), elevated preoperative plasma 
vWf was the only laboratory variable significantly 
predictive of poor outcome. A final model for out- 
come was produced based on systolic anlde pressure 
(relative hazard for lower quartile (<50 mm Hg) 
versus upper quartile (>100 mm Hg) = 2.51, 95% CI 
1.36 to 4.62), presence of limb sepsis or tissue 
necrosis (relative hazard = 2.73, 95% CI 1.44 to 
5.15), female sex (relative hazard= 1.90, 95% CI 
1.00 to 3.60), and preoperative plasma vWf level 
(relative hazard UQ [>185 IU/dl]  vs LQ [<96 
IU/ctl] = 1.83, 95% CI 1.38 to 2.44). No other 
variables were able to improve on the model, and tests 
for interactions among these four variables indicated 
that no statistically significant interactions occurred 
among them. 
The coefficients from this final Cox proportional 
hazards model were then scaled and rounded to 
give the risk scoring system: Score -~ vWf (IU/dl) - 
(3 x systolic ankle pressure (mm Hg))+ 94 (if fe- 
male) + 150 (if infection). The higher the risk score 
was, the greater the incidence of death or graft 
occlusion was. Cox model survival curves for differing 
risk scores are illustrated in Fig. 3. 
DISCUSSION 
The patency rates for this series of consecutive 
femoropopliteal and femoro-distal grafts are similar to 
results reported from other centers, 23-26 and the study 
confirms that a large number of patient and graft 
characteristics are associated with the outcome of 
infrainguinal bypass grafting. 6'27-a° The 27% 1-year 
occlusion rate in this group of patients may be related 
to the unselectcd nature of the patients tudied, and 
although only 38% of bypasses were performed for 
critical imb ischemia when the European consensus 
definition 2° was strictly applied, had we used other less 
rigid criteria of definition, 31 most of the grafts would 
have been classed as being "limb salvage" procedures. 
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Fig. 1. Cumulative primary assisted patency rates at 1 year, by graft material, in 184 
infrainguinal bypass grafts. Numbers alongside ach survival curve refer to numbers at risk at each 
time point. 
Table II. Relation of preoperative smoking markers, hemorheology, and biochemistry to graft 
outcome after infrainguinal bypass grafting. Values are median (interquartile range) 
Variable Good outcome (n = 117) Graft occlusion (n = 50) Postoperative death (n = 17) 
Cotinine (ng/ml) 66 (4-214) 66 (13-234) 32 (5-285) 
Thiocyanate (gmol/L) 49 (32-106) 52 (25-108) 37 (30-57) 
CarboxyHb (%) 1.00 (0.60-2.20) 1.1 (0.8-2.7) 1.3 (0.8-3.1) 
Hemoglobin (gm/dl) 14.0 (13.0-14.9) 12.2 (10.8-13.5) 11.8 (11.1-12.5) 
Hematocrit (%) 44 (41-46) 39 (35-45) 38 (37-42) 
Platelets (x109/L) 240 (212-287) 312 (237-377) 336 (289-413) 
White cells (xl09/L) 7.9 (6.8-9.6) 8.7 (7.2-11.6) 12.4 (7.8-12.8) 
Plasma viscosity (mPa.s) 1.32 (1.28-1.38) 1.36 (1.28-1.45) 1.44 (1.2%1.54) 
Whole blood viscosity (mPa) 3.27 (2.90-3.68) 2.92 (2.70-3.17) 3.21 (2.58-3.32) 
Corrected blood viscosity (mPa) 3.37 (3.14-3.56) 3.33 (3.11-3.60) 3.55 (3.09-3.78) 
Relafiveviscosity 2.52 (2.36-2.71) 2.42 (2.25-2.64) 2.44 (2.14-2.65) 
Red cell aggregation (Myrenne units) 4.6 (3.6-5.7) 4.2 (3.4-5.4) 3.4 (2.1-6.5) 
Cholesterol (mmol/L) 5.8 (4.9-6.7) 5.2 (4.2-6.2) 3.8 (3.3-4.7) 
Serum albumin (gin/L) 42 (39-44) 38 (34-43) 33 (31-38) 
Serum globulin (gin/L) 24 (22-27) 27 (23-29) 29 (25-32) 
C-reactive protein (gm/L) 7 (5-14) 14 (5-110) 26 (13-64) 
Fibfinogen (gm/L) 3.3 (2.8-4.2) 4.3 (3.2-4.9) 4.5 (3.5-5.5) 
FDP (ng/ml) 155 (104-279) 240 (142-392) 360 (196-655) 
von Willebrand factor (Iu/dl) 117 (91-175) 176 (122-252) 322 (174-370) 
t-PA (ng/ml) 8.5 (6.5-10.7) 7.8 (5.7-11.8) 9.5 (9.2-10.7) 
Factor VII (%pool) 109 (90-118) 99 (79-109) 92 (72-105) 
PAI(%pool) 119 (83-166) 112 (91-151) 112 (90-128) 
t-PA, Tissue-type lasminogen activator; PAI, plasminogen activator inhibitor. 
In addition, half of the procedures in this study were 
carried out in patients who had undergone previous 
revascularization surgery for arterial disease, indicat- 
ing that these were patients with advanced long- 
standing disease. 
The effect of counting limbs rather than patients 
in the multivariate analysis resulted in 21 repeat grafts 
(either edo procedures after graft occlusion or a graft 
inserted into the other limb in patients with bilateral 
disease) being included in the study. This practice may 
introduce slight bias into an analysis that is dependent 
on all the observations being completely indepen- 
dent, although it significantly increases the statistical 
power of the study. Several of the prognostic factors 
that we analyzed were specific to the graft (e.g., 
material) or specific to the patient at the time of 
operation for a particular graft, and the dynamic 
nature of most of the variables analyzed was taken into 
account by repeating the "baseline" measurements in 
all patients before undertaking a second procedure. 
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Fig. 2. Infrainguinal graft patency by preoperative l vels 
of potential thrombotic mediators: fibrinogen, FDP, and 
vWf. Numbers below each survival curve refer to numbers 
at risk at each time point. 
Most of these values would differ from the baseline 
data for the first graft, and we therefore believe that we 
are justified in including second procedures in the 
final analysis. 
We have confirmed that preoperative plasma fi- 
brinogen is a predictor of infrainguinal graft occlu- 
sion 32 or death; other investigators have shown that 
postoperative fibrinogen is associated with graft oc- 
clusion. 9,~° Raised fibrinogen levels might promote 
graft occlusion through increased thrombus 
formation; we found that raised levels of cross-linked 
FDP (a marker of increased fibrin turnover) were also 
predictive of poor outcome. Raised fibrinogen levels 
might also promote graft occlusion through increased 
plasma and blood viscosity; however, our data do not 
support this. Alternatively, the association between 
preoperative fibrinogen and graft occlusion may re- 
flect mutual associations with extent of arterial dis- 
ease, ss infection, or smoking) °'~s This possibility is 
supported by the finding that the associations of 
fibrinogen and FDP with poor outcome were no 
longer significant on multivariate analysis including 
preoperative patient characteristics. 
Subendothelial proliferation and thrombus for- 
marion are key processes in infrainguinal graft occlu- 
sion. n~13 Plasma vWf is a marker of endothelial 
disturbance (e.g., after percutaneous angioplasty 34) 
and is a major cofactor in platelet adhesion and 
aggregation. 3sIt is an essential requirement for the 
development of occlusive thrombi at sites of arterial 
injury. 14 We have shown for the first time that preop- 
erative plasma vWf is a strong predictor of poor 
outcome within a year ofinfrainguinal revasculariza- 
tion (Fig. 2), which on multivariate analysis was 
independent of patient characteristics and when 
added to three patient characteristics (low ankle 
systolic blood pressure, female sex, and presence of 
limb sepsis or tissue necrosis) gave a predictive index, 
which shows potential clinical applicability, for ex- 
ample, patient selection for infrainguinal revascular- 
ization surgery (Fig. 3). This index requires validation 
in prospective studies. 
The association of high vWf with poor outcome 
of graft surgery may reflect its association with endo- 
thelial disturbance and its important roles in platelet 
thrombus formation.14,35 The importance ofplatelets 
in graft occlusion has been shown by a metaanalysis of
randomized controlled trials of antiplatelet agents, 36 
and the association in this nonrandomized study of 
antiplatelet agents with good outcome, although the 
effect of antiplatelet therapy on graft function re- 
quires further investigation with appropriately de- 
signed studies. Our findings are consistent with in- 
creasing appreciation of the association of vWf with 
arterial disease s7 and suggest that antithrombotic 
treatment directed against vWf (e.g., its binding to 
platelet receptors) merits attention, ss We found that 
two other markers of endothelial disturbance (tissue- 
type plasminogen activator and plasminogen activator 
inhibitor) were not predictive of poor outcome; hence 
this endothelial disturbance appears confined to vWf. 
As regards other risk predictors, we confirmed an 
association between low cholesterol and poor out- 
come after graft surgery.l° We suggest that this finding 
may reflect the association of severe arterial disease 
with acute phase responses of laboratory tests (low 
levels of cholesterol, albumin, factor VII, hematocrit, 
hemoglobin, and high levels of CRP, fibrinogen, 
plasma viscosity, platelet count, and white cell 
count), ss Limb sepsis and tissue necrosis were inde- 
pendent predictors of poor outcome in this study, 
possibly mediated by effects of such acute-phase 
reactants. 
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Fig. 3. Cox model survival curves for infrainguinal bypass grafts based on risk assessment score. 
The predictive value of low anlde systolic pressure 
(disease severity) and female sex may reflect he effects 
of small vessel diameter. That both a low anlde systolic 
pressure and the presence of limb sepsis or tissue 
necrosis are independently predictive of a poor out- 
come after surgery and that both of these criteria 
are associated with the diagnosis of critical limb 
isehaemia, 2° suggest hat the outcome after infrain- 
guinal grafting will be poorer in patients with critical 
ischemia. 
This study failed to demonstrate any significant 
effect of smoking habit or graft material on the 
outcome after surgery in this study, in contrast o 
findings in other series. 6'1° Although smoking often 
appears to influence patient selection for graft sur- 
gery, a8 our results suggest hat laboratory variables 
such as vWf may be more accurate predictors of 
adverse outcome after infrainguinal graft surgery, 
possibly because they are markers of key biologic 
processes in graft occlusion and arterial disease pro- 
gression. We therefore suggest that further studies of 
thrombotic variables and graft surgery may be both 
biologically interesting and clinically useful. 
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